STRONG CHILDREN'S RESEARCH CENTER

Summer 2014 Research Scholar

Name: Allison Eberhardt

School: University of Rochester

Mentor: Jason Mendler, M.D., Ph.D.

ABSTRACT

Title: Treatment of RUNX1-Mutated Acute Myeloid Leukemia with Focal Adhesion Kinase Inhibitors

Background:

tion is a loss-of- ing and non-expressing cell lines at 24 hours, as well as sample 121813.
Lower concentrations (100 nM, 1 µM) of a Compound 14 engrafted AML mice. Because 121813
expresses phospho-FAK so highly, it is a good sample on which to test the efficacy of FAK inhibitors both *in vitro* and *in vivo*.

Low doses of the FAK inhibitors Compound 14 and PF-562271 had little effect on the colonizing ability of both FAK expressing and non-expressing cells. Although doses higher than 10 mM were toxic to both FAK expressers and non-expressers in culture, we believe that the lower concentrations are capable of effectively inhibiting FAK; the process of lysing he cells has yet to be optimized.